rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment

DOI: 10.1016/j.jvacx.2019.100009

Keywords: Vaccines, Ebola vaccine, Vesicular stomatitis virus vector, Viral vector, Brighton collaboration, Risk/benefit assessment, Vaccine safety

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text